secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-05-19T23:59:59+00:00
Accession:  0001628280-22-014881
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex forms JV to commercialize Tru Niagen in China; gets 71% voting interest
--------------------------------------------------------------------------------

- JV partners Crystal Lake, Pioneer Idea, Taikuk contribute $1.8M, $1.2M, $1.0M total $4M into the JV.
- ChromaDex holds 71% voting interest, appoints 3 of 5 directors; Taikuk gets 11% non-voting interest after $1M fee.
- JV to commercialize Tru Niagen and other NR products in Mainland China (excl. HK, Macau, Taiwan) under 20-year term.
- Health food (Blue Hat) registration with China SAMR required for broad distribution; must be obtained within 24 months of closing.
- JV expects to enter distribution agreement with Sinopharm Xingsha upon regulatory approval; closing targeted by Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022014881/0001628280-22-014881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022014881/cdxc-20220519.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-014881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer